DOCSLIB.ORG

Index Vol. 12-15

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252 311 14 Adreson N® 141 13 3-Acetoxybenzoquinuclidine 312 14 Adsorbentien 363, 365 15 trans-( + )-2-Acetoxy-cyclopropyltrime- 14 Adsorption 363 thylammonium 250 14 Aerosolpraparate 324 12 170(-Acetoxyprogesterone 78 13 Aescin 35, 64 13 3-Acetoxyquinuclidine 307,330 15 Agantuka 15 13 2-Acetylaminofluorene 145 14 Agrocybin 530 13 Acetylations 149 14 Agropyren 478, 517, 525 14 Acetylcholine 35, 43, 77, 86, 89 14 Agropyron repens (L.) 517, 525 13 Acetylcholine, antagonists of 37 13 Ajmalicine 19 14 Acetylcholine esterase 23, 84 12 Ajmaline 296, 313 13 Acetylcoenzyme A 258 13 - 48, 57, 60 14 Acetylen 389 13 Ajmaline camphor-10-sulphonate 62 14 Acetylen-Verbindungen 487,525 13 Akuammidine 50 13 N-Acetylneuraminic acid 345 13 Akuammine 50 14 Acetylphenylacetylen 482 14 Albumin 24, 74, 75, 105 13 2-Acetylquinuclidine-3-acetic acid, 12 Alcacyl 238 derivatives of 300 12 Alderline 322 13 Acetylsalicylic acid 160 14 Aldosterone 124, 125 12 Achromobacter 372 15 Alkaloids 216 14 Acidic polysaccharides 93 14 Alken-(1)-in-(4)-ole-(3)-carbamate 397 12 Aconcen® 151 14 Alkindiole-(1,2) 417 12 Aconitine 313 14 Alkinole 390 12 ACTH (Adrenocorticotropic hormone, 14 Alkin-(2)-ole-(1), tertiare 407 adrenocorticotropin) 16, 30, 155 14 Alkin-(3)-ole-(1), terti are 396,408 14 - 149, 153, 163, 165, 167, 171 14 N-Alkinyl-athanolamine 422 15 - 216 14 Alkinyl-Barbitursauren 422 14 Actinomycin 103 14 1-Alkinyl-4-phenylpiperidinole-(4), Ester 13 4'-(N-Acylsulfanilyl)ar,Hides 192 463 12 Adams-Stokes syndrome 337, 339 14 4-Alkinylpiperidinol-(4)-ester 457 12 Addis co un t 444 13 3-Alkoxycarbonylmethylene-quinucli- 12 Addison's disease 140 dines 303 23 Jucker 15 354 Index \'01. 12-15 14 K-Alkyl-N-alkinyl-1-aminoindane 456 12 Aminoglycoside 386 14 2-Alkyl-3-aryl-4-quinazolone 226 15 1-Amino-2-( 4-imidazol yl)cyclopropane­ 13 3-Alkyl(aryl)-quinuclidines 303 carboxylic acid 253 13 Alkylguanidines 110 13 N-Amino-methyldopa (MK-485) 105 14 3-Alkyl-4-propin-(2)-ylpiperidinole-( 4), 15 6-Amino-penicillanic acid 214 Ester 462 14 2-Amino-pentin-(4)-saure 481 14 4-(1)-Alkylpropin-(2)-yl)-piperidinole-( 4), 15 p-Aminophenol 153 Ester 463 15 1- (4-Aminophen yl)-I-(2-amino-4- 14 2-Alkyl-4(3H)-quinazolones 253 thiazol yl)cyclopropanc 253 15 Allethrin 264 14 Aminophyllin 281 12 Allochrysin 229 12 Aminopterin 218, 220 13 Alloferin 37, 38 12 Aminopyrin (Aneuxol, Dimapyrin, 12 Allopurinol (Zyloric) 32, 286, 287 Dipyrin, Pyramidon) 22, 240 15 - 217 14 - 359 13 Allosteric inhibition 49 14 2-Amino-4(3H)-quinazolones 248 14 - 42 13 4-Aminoquinolines 176,177,178,207 14 Alloxan 199 14 - 76 15 5-Allyl-5-bromcyclohexenyl-thiobarbi- 13 8-Aminoquinolines 210 turat 150 14 - 76 12 Allylestrenol (Gestanon®) 150, 152 13 4-Aminoquinoline salts 208 14 DL-5-AUyl-5-(1-methylpentin-(2)-yl)-2- 13 3-Aminoquinuciidine 305 thiobarbitursaure 403 13 4-Aminoquinuclidine 305 12 Alphaprodine 21 12 p-Aminosalicylic acid 19 12 Alpha-receptor-blocking agents 324 14 p-Aminosalizylsaure (PAS) 305 14 Alprenolol 38 15 1-( 2-Amino+ thiazol yl) -2-( 4-amino­ 15 - 113 phenyl)cyclopropane 253 12 Alseroxylon 314 13 Amiquinsin 124 14 Aluminiumhydroxyd 320 14 Amisometradine 24 14 Aluminiumoxid 363 12 Amitriptylin(Elavil, Laroxyl, Saroten, 15 Amanita muscaria 73 Tryptizol) 208, 316 12 Amantadine 19 15 Amobarbital 189 13 - 163 14 Amobarbital-Natrium 281 12 Ambonestyl 306 13 Amodiaquine 176, 178 12 Amenorrhoea 59, 66 13 Amoebiasis 33 12 Amethopterin 17, 218, 221 12 Amotriphene (Myordil) 317 13 - 156 12 Amphetamin(e) 24 13 Amethopterin, plasma levels of 159 14 - 18 13 Amidopyrine 161 15 - 161 13 Amidopyrine, demethylation of 162 12 Amphotericin B 19 13 Amino acid conjugations 149 15 - 215 13 9-Aminoacridines 207 12 Ampicillin 378, 379 14 1-Amino-acyl-2,3-dihydro-4(IH)- 14 Amylopectin 88 quinazolones 261 14 Amylose 345, 363 14 2-Aminoalkin-(4)-diole-(1,3) 402 13 [J-Amyrin 35 14 w-Amino-alkin-(l)-ole 439 13 Amyzil 318 14 Aminoalkinole, quart are 427 12 Anabolic steroids 142, 143 14 3-(tert.-Aminoalkinyl)-1-methylpiperidine 15 Anaemia 39, 54 463 13 Anaesthesia 331 13 3-Aminoalkoxyquinuclidine derivatives 14 Analeptica 441 315 13 Analgesic acitivity 160 13 Aminoalkyl-guanidines 116 12 Analgesic agents 21 14 4-Aminoantipyrin 355 14 - 225, 234 12 p-Aminobenzonic acid (PABA) 391 12 Analgesine 240 15 - 281, 293, 307 12 Analgetika 240 15 4-Aminobiphenyl 173 15 - 186 14 4-Amino-butin-(2)-ole-(1) 438, 439, 446 14 Analgetische Wirkung 457,459, 460 14 4-Amino-butin-(2)-01-(1), Ester 436, 13 Anaphylactic shock 353 437, 442 14 - 207 14 4-Amino-butin-(2)-ol-(1), 13 Anaphylactoid oedema 350 N-Pheny1carbamate 437 14 Anaphylactoid reaction 197 14 1-( 4-Aminobutin-(2)-yl)-barbitursauren 13 Anaphylatoxin 354 424 13 Anaphylaxis 347, 353 14 1,3-(4-Aminobutin-(2)-yl)-barbitur- 15 Anatomy 36 sauren 424 12 Androgen 146 14 N-(4-Aminobutin-(2)-yl)-dicarbonsaure- 12 Androgenic activity 145 imide 429, 434 12 Androgenic steroids 142, 143 13 €-Aminocaproic acid 357 12 Androgens 81 15 1-Amino-trans-2- [4-( 3, 5-dibromo-4- 14 Androstanolone 163, 164, 183 hydroxyphenoxy)-3,5-diiodophenyIJ 14 4-Androsten-3,17-dione 153 cyclopropanecarboxylic acid 253 14 Androstenediol dipropionate 163 14 Q(-Aminoessigsaure 357 13 Androstenedione 272 Index Yol. 12-15 355 14 Andros teron 314 14 Antidepressiva 453 13 Androsterone 271 12 Antidepressive agents 315 14 Anemia 177,178 12 Antidiabetes agents 16 14 Anesthesia 105, 107 14 Antidotal action 22 15 - 85 14 Antidote 20, 365 12 Anesthetics 21 14 An tiepileptic action 228, 229 14 - 105 12 Antiepileptics 314 12 Aneural 190 12 Antifertility effects 110 12 Aneuxol 240 13 Antigen 353 14 Angina pectoris 452 12 Antihaemorrhagic activity 147 14 Angioedema 214 12 Antihistamine 30, 309 13 Angbneurotic oedema 351 14 - 92,93,95 12 Angiotensine 333, 334 14 Antihistaminic activity 258 12 Anileridine 21 15 Antihistaminikum 194 13 Anilin(e) 161 14 Antihistaminische Wirkung 404 15 - 153,170,172 14 Antihypertensive activity 245 13 Anisatin 64 12 Antihypertensive agents 28 15 Anna 16 13 - 104 15 Anorectic activity 244 14 - 246, 247 14 Anorexia nervosa 182 14 Antihypertonikum 467 12 Anovlar® 150 14 Anti-infectious agents 45, 46, 50 13 Ansiv (HT-1479) 121 13 Anti-inflammatory action 62 15 Antagonism 317,321 14 - 254 14 Antagonism, irreversible 44 15 Anti-inflammatory activity 257 14 Antagonists 35, 36, 39 13 Anti-inflammatory agents 36 12 Antazoline (Antistine) 310 14 - 70, 73, 174, 234 15 An thelmin tic agent 143 15 - 221 14 Anthelmintische Wirkung 396 15 An tikoagulan tien 150 13 Anthrone glycosides 28 14 Antikonvulsive Wirkung 401, 404 14 Antiadrenergic activities 261 14 Antikonvulsivum 395, 399 13 Anti-amoebal drug 39 12 Antileukemic agent 17 14 Antiamoebic action 256 13 Antimalarial activity 174, 178 12 Antiandrogen 146 14 - 225 12 Antianginal agents 27 13 Antimalarial drugs 171, 207 15 Antianxiety agent 265 14 - 76, 221 12 Antiarrhythmic action 299 13 Antimalarial drugs, classification of 172 14 - 111 13 Antimalarial drugs, degradation of 178 12 Antiarrhythmic activity 297, 308, 336 13 Antimalarial drugs, excretion of 178 12 Antiarrhythmic agents 293, 303, 344 12 An timalarials 300 12 Antiarrhythmic drugs 294, 295, 336 12 Antimalariamittel 230 12 Antiarrhythmic effect 294, 296 12 Antirnalariarni ttel, N e benerschein un gell 12 Antibacterial activity 441 231 14 - 259 14 Antimetabolites 38 15 - 337 15 Antimicrobial activity 334 12 Antibacterial agents, testing 444 12 Antimicrobic drugs 374 12 Antibacterial substances 396 15 - 283 15 Antibiotic action 313 14 Antimikrobielle Wirkung 486 15 Antibiotic combinations 317 14 Antimitotic activity 260 15 Antibiotic concentration 311, 288 15 Antimycobacterial activity 253 12 Antibiotics 380, 383 14 Antimykotikum 485 14 -101 13 Antineoplastic drug 32 15 - 214, 285 12 Antioestrogens 113, 114 12 Antibiotika 215 14 Antiparkinson-Mittel 436 14 Antiblastin 528 12 Antiphlogistika 240 13 Anti-cancer agents 31 14 Antiphlogistische Wirksamkeit 459 14 Anticholinerge Wirkung 437 14 Antipyretic agents 234 13 Anticholinergic activity 319 14 Antipyretische Eigenschaften 404 13
Recommended publications
  • Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N

    Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N

    RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees.
  • The Use of Plants in the Traditional Management of Diabetes in Nigeria: Pharmacological and Toxicological Considerations

    The Use of Plants in the Traditional Management of Diabetes in Nigeria: Pharmacological and Toxicological Considerations

    Journal of Ethnopharmacology 155 (2014) 857–924 Contents lists available at ScienceDirect Journal of Ethnopharmacology journal homepage: www.elsevier.com/locate/jep Review The use of plants in the traditional management of diabetes in Nigeria: Pharmacological and toxicological considerations Udoamaka F. Ezuruike n, Jose M. Prieto 1 Center for Pharmacognosy and Phytotherapy, Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, 29-39 Brunswick Square, WC1N 1AX London, United Kingdom article info abstract Article history: Ethnopharmacological relevance: The prevalence of diabetes is on a steady increase worldwide and it is Received 15 November 2013 now identified as one of the main threats to human health in the 21st century. In Nigeria, the use of Received in revised form herbal medicine alone or alongside prescription drugs for its management is quite common. We hereby 26 May 2014 carry out a review of medicinal plants traditionally used for diabetes management in Nigeria. Based on Accepted 26 May 2014 the available evidence on the species' pharmacology and safety, we highlight ways in which their Available online 12 June 2014 therapeutic potential can be properly harnessed for possible integration into the country's healthcare Keywords: system. Diabetes Materials and methods: Ethnobotanical information was obtained from a literature search of electronic Nigeria databases such as Google Scholar, Pubmed and Scopus up to 2013 for publications on medicinal plants Ethnopharmacology used in diabetes management, in which the place of use and/or sample collection was identified as Herb–drug interactions Nigeria. ‘Diabetes’ and ‘Nigeria’ were used as keywords for the primary searches; and then ‘Plant name – WHO Traditional Medicine Strategy accepted or synonyms’, ‘Constituents’, ‘Drug interaction’ and/or ‘Toxicity’ for the secondary searches.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Pp375-430-Annex 1.Qxd

    Pp375-430-Annex 1.Qxd

    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test

    Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test

    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
  • The Nutrition and Food Web Archive Medical Terminology Book

    The Nutrition and Food Web Archive Medical Terminology Book

    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
  • (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker Et Al

    US 2011 002841 8A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker et al. (43) Pub. Date: Feb. 3, 2011 (54) USE OF GABBA RECEPTOR ANTAGONISTS Publication Classification FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCATED (51) Int. Cl. WITH EXCESSIVE SLEEPINESS A63L/7028 (2006.01) A 6LX 3/557 (2006.01) (75) Inventors: Kathy P. Parker, Rochester, NY A63L/335 (2006.01) (US); David B. Rye, Dunwoody, A63L/4355 (2006.01) GA (US); Andrew Jenkins, A63L/047 (2006.01) Decatur, GA (US) A6IP 25/00 (2006.01) Correspondence Address: (52) U.S. Cl. ........... 514/29: 514/220; 514/450, 514/291; FISH & RICHARDSON P.C. (AT) 5147738 P.O BOX 1022 Minneapolis, MN 55440-1022 (US) (57) ABSTRACT (73) Assignee: Emory University, Atlanta, GA GABA receptor mediated hypersomnia can be treated by (US) administering a GABA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and (21) Appl. No.: 12/922,044 oenanthotoxin). In some embodiments, the GABA receptor antagonist is flumazenil or clarithromycin. The GABA (22) PCT Filed: Mar. 12, 2009 receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narco (86). PCT No.: PCT/USO9/37034 lepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hyperSonmia; endozepine related S371 (c)(1), recurrent stupor; and amphetamine resistant hyperSonmia), (2), (4) Date: Sep. 10, 2010 and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and Related U.S. Application Data hypersomnia (e.g., idiopathic hypersomnia; recurrent hyper (60) Provisional application No.
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.